Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 9/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | TGM2 | P21980 | 1/20 | 0.56 |
| ▸ | KCNMA1 | Q12791 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18256266 | 0.86 | TGM2 (0.59) | GAASMN1; SMN2MAPTTGM2MEN1 | |
| SCHEMBL21894170 | 0.84 | TGM2 (0.58) | GAASMN1; SMN2MAPTTGM2MEN1 | |
| SCHEMBL31162390 | 0.84 | TGM2 (0.58) | GAASMN1; SMN2MAPTTGM2MEN1 | |
| SCHEMBL17524715 | 0.81 | TGM2 (0.54) | GAASMN1; SMN2MAPTTGM2TP53 | |
| SCHEMBL15938644 | 0.81 | TGM2 (0.54) | GAASMN1; SMN2MAPTTGM2TP53 | |
| SCHEMBL14354684 | 0.81 | GAA (0.74) | GAASMN1; SMN2MAPTKCNMA1NPC1 | |
| SCHEMBL31162339 | 0.81 | MEN1 (0.61) | SMN1; SMN2MAPTTGM2NPC1TP53 | |
| SCHEMBL5078477 | 0.81 | MEN1 (0.61) | SMN1; SMN2MAPTTGM2NPC1TP53 | |
| SCHEMBL23652898 | 0.80 | TGM2 (0.53) | GAASMN1; SMN2MAPTTGM2MEN1 | |
| Hydrochloric Acid SCHEMBL18249511 | 0.80 | TGM2 (0.53) | GAASMN1; SMN2MAPTTGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108291001-B | Urethane-modified (meth) acrylamide compound and active energy ray-curable resin composition containing same | 科巨希化学股份有限公司 | 2020-11-17 | — | — | CN | disclosed |
| US-10759897-B2 | Urethane-modified (meth)acrylamide compound and active energy ray curable resin composition containing same | KJ CHEMICALS CORPORATION (JP) | 2020-09-01 | — | — | US | disclosed |
| US-20180244832-A1 | URETHANE-MODIFIED (METH)ACRYLAMIDE COMPOUND AND ACTIVE ENERGY RAY CURABLE RESIN COMPOSITION CONTAINING SAME | KJ CHEMICALS CORPORATION (JP) | 2018-08-30 | — | — | US | disclosed |
| EP-3333208-A1 | URETHANE-MODIFIED (METH)ACRYLAMIDE COMPOUND AND ACTIVE ENERGY RAY CURABLE RESIN COMPOSITION CONTAINING SAME | KJ Chemicals Corporation (JP) | 2018-06-13 | — | — | EP | disclosed |
| EP-1891064-B1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | ALMIRALL SA (ES) | 2009-09-02 | — | — | EP | disclosed |
| EP-1891064-B1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | ALMIRALL SA (ES) | 2009-09-02 | — | — | EP | disclosed |
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-05-21 | — | — | US | disclosed |
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-05-21 | — | — | US | disclosed |
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-05-21 | — | — | US | disclosed |
| EP-1891064-A1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | Laboratorios Almirall, S.A. (ES) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006133802-A1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-12-21 | — | — | WO | disclosed |
| EP-0508334-B1 | Novel aminophenol derivatives and pharmaceutical compositions thereof | GREEN CROSS CORP (JP) | 1998-01-07 | — | — | EP | disclosed |
| US-5308840-A | Antioxidants, antiallergens and antiinflammatory agents | GREEN CROSS CORPORATION (JP) | 1994-05-03 | — | — | US | disclosed |
| EP-0508334-A2 | Novel aminophenol derivatives and pharmaceutical compositions thereof | THE GREEN CROSS CORPORATION (JP) | 1992-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759897-B2 | Urethane-modified (meth)acrylamide compound and active energy ray curable resin composition containing same | RAD51, UNC119, ULK2 | GAA 4103/4885SMN1; SMN2 2792/4885MAPT 164/4885 |
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | CCR1, CCR3, CCR8 | GAA 4088/4885SMN1; SMN2 2591/4885MAPT 4128/4885 |
| US-20180244832-A1 | URETHANE-MODIFIED (METH)ACRYLAMIDE COMPOUND AND ACTIVE ENERGY RAY CURABLE RESIN COMPOSITION CONTAINING SAME | RAD51, UNC119, ULK2 | GAA 4103/4885SMN1; SMN2 2792/4885MAPT 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.